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To the Editor: 
 
Recently, we had the opportunity to read the article by Doyle et al [1]. Prior studies of the 1980s 
used considerably large cumulative doses of dexamethasone (DEX) for preterm infants (usually > 
3 mg/kg over 1–6 weeks, started after 2 weeks of age). Newer studies in the 1990s applied DEX to 
preterm infants with respiratory distress deemed to be at risk for developing BPD. Early postnatal 
administration of DEX (started before 2 weeks of age) has been based on this contention. The 
cumulative DEX doses in the early protocols were considerably lower (usually < 3 mg/kg) than in 
the delayed protocols. It is noteworthy that the very preterm infants studied by Doyle et al. 
received lower end of the range of doses used for any reported trials (0.89 mg/kg over 10 days, 
started at 0.15 mg/kg per day). In 1999, we reported that early (4–7 days of age) low-dose DEX 
therapy (0.125 mg/kg, every 12 h, for 6 doses) facilitated extubation and improved the clinical 
outcome in preterm infants with respiratory distress [2]. Infants in our study were somewhat 
mature at birth than were those in the study by Doyle et al. (mean gestational age: 28 weeks vs. 25 
weeks). Absence of significant steroid adverse effects is probably explained by the low doses of 
DEX treatments in both studies. 
 
Jobe [3] stated that the “standard” initial dose of 0.5 mg/kg per day DEX (equivalent to 12 mg of 
cortisol) is extremely high relative to the 24-h basal production rate of about 0.5 mg cortisol for a 
preterm infant weighing 1 kg and a stress production rate of about 1.5 mg per day. The initial dose 
of 0.1–0.2 mg/kg per day DEX should be sufficient and might be too high for preterm infants. The 
dose and duration of DEX therapy should be limited to the minimum necessary to achieve the 
desired effects. Recently, we conducted an observational study in which we used an even lower 
dose of DEX (0.06 mg/kg, once or twice per day) for an even shorter interval (1–2 days) [4]. 
Short-term beneficial clinical effects were readily apparent. For that reason, it can be 
recommended that a low dose (0.06 mg/kg, once or twice per day) of DEX be administered to 
very preterm infants at risk for BPD as a short-term (1–2 days) pulse – with administration started 
at 4–7 days of age and repeated periodically (e.g. once per week) if necessary – to provide 
treatment benefits while attenuating the risk of possible adverse effects. 
 
Preterm infants with BPD are now much less mature than originally described over 30 years ago. 
In addition to its changing epidemiology, the nature of BPD has also evolved, such that 
pathological signs of severe chronic lung injury with striking fibrosis and cellular proliferation 
are less common. Disruption of the normal sequence of lung development, engendering alveolar 
simplification and dysmorphic vascular growth, is the hallmark of new BPD. We hope that new 
strategies for maturing very preterm lung (e.g., using angiogenic factors or tissue survival factors) 
can yield treatment alternatives and minimize the cumulative DEX doses in the respiratory care of 
very preterm infants. 
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